[Endothelium derived relaxing factor and its effect on vascular disease].
The finding of endothelium derived relaxing factor (EDRF) and the illumination of its chemical identity, bio-synthesis and physiological functions promoted greatly the research on vascular disease. The EDRF was verified as NO or R-O-NO by many experimental results, and several pathological processes such as hypertension, atherosclerosis and heart failure were considered to be associated with abnormalities of endothellium-dependent vascular relaxation and decrease of basal EDRF and/or storage EDRF. As the provider of EDRF, Nitryl vascular relaxation substance could remedy EDRF and might play an important role in clinical therapy and prevention of human vascular disease.
Wang
Jufang
J
College of Food and Bioengineering, South China University of Technology, Guangzhou 510640, China.
Li
Zhiyong
Z
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D004285:Dogs; D045462:Endothelium-Dependent Relaxing Factors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D009569:Nitric Oxide / Q000502:physiology; D011817:Rabbits; D051381:Rats; D013552:Swine; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use
D045462:Endothelium-Dependent Relaxing Factors; D014665:Vasodilator Agents; D009569:Nitric Oxide